COM:JASPERTHERAPEUTICS
Jasper Therapeutics
- Stock
Last Close
21.84
22/11 21:00
Market Cap
299.75M
Beta: -
Volume Today
95.90K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 47.74K - | 47.74K 0% | ||||
average payables | 708.50K - | 2.67M 276.57% | 2.84M 6.58% | 2.96M 4.04% | ||
average receivables | 300K - | 300K 0% | 331.50K 10.50% | 331.50K 0% | ||
book value per share | -0.93 - | 6.10 756.80% | 0.99 83.83% | 0.01 99.24% | ||
capex per share | -0.21 - | -0.02 92.59% | -0.00 99.84% | |||
capex to depreciation | -6.44 - | -0.59 90.83% | -0.24 59.21% | |||
capex to operating cash flow | 0.07 - | 0.01 82.58% | 0.01 59.17% | |||
capex to revenue | ||||||
cash per share | 0.52 - | 7.43 1,317.11% | 1.05 85.90% | 0.01 99.21% | ||
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.07 - | 0.03 55.70% | 0.08 145.07% | 0.03 61.11% | ||
debt to equity | -0.05 - | 0.04 189.77% | 0.10 144.45% | 0.04 64.99% | ||
dividend yield | ||||||
earnings yield | -0.08 - | -0.27 220.53% | -1.37 411.60% | |||
enterprise value | 360.33M - | 7.62M 97.88% | -16.98M 322.66% | 82.28B 484,731.40% | ||
enterprise value over ebitda | -36.74 - | -0.18 99.52% | 0.26 249.70% | -1.19K 451,372.12% | ||
ev to operating cash flow | -19.73 - | -0.23 98.85% | 0.37 263.52% | -1.58K 426,939.01% | ||
ev to sales | ||||||
free cash flow per share | -0.48 - | -3.17 556.03% | -1.27 59.84% | -0.01 99.61% | ||
free cash flow yield | -0.05 - | -0.40 736.54% | -2.64 552.77% | -0.00 99.98% | ||
graham net net | -1.01 - | 5.32 626.90% | 0.72 86.40% | 0.01 99.07% | ||
graham number | 4.18 - | 17.00 306.32% | 3.83 77.44% | |||
income quality | 0.58 - | 1.10 90.58% | 1.22 10.70% | 0.81 33.63% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | 3.79 - | |||||
interest debt per share | 0.04 - | 0.25 489.62% | -0.27 206.74% | 0.00 100.10% | ||
inventory turnover | ||||||
invested capital | -0.05 - | 0.04 189.77% | 0.10 144.45% | 0.04 64.99% | ||
market cap | 378.54M - | 89.44M 76.37% | 17.62M 80.30% | 82.36B 467,314.83% | ||
net current asset value | 100.15M - | -37.80M 137.74% | 63.70M 268.50% | 29.36M 53.91% | 72.49M 146.90% | |
net debt to ebitda | 1.86 - | 1.90 2.20% | 0.54 71.57% | 1.22 126.34% | ||
net income per share | -0.84 - | -2.11 151.36% | -0.66 68.52% | |||
operating cash flow per share | -0.48 - | -2.96 511.92% | -1.26 57.47% | -0.00 99.60% | ||
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -1.36 - | -0.26 81.11% | -0.50 95.19% | |||
revenue per share | ||||||
roe | 0.90 - | -0.35 138.27% | -0.67 94.69% | |||
roic | 0.65 - | -0.38 159.11% | -0.76 98.08% | |||
sales general and administrative to revenue | ||||||
shareholders equity per share | -0.93 - | 6.10 756.80% | 0.99 83.83% | 0.01 99.24% | ||
stock based compensation to revenue | ||||||
tangible asset value | 100.15M - | -35.13M 135.08% | 69.52M 297.89% | 35.99M 48.23% | 78.44M 117.96% | |
tangible book value per share | -0.93 - | 6.10 756.80% | 0.99 83.83% | 0.01 99.24% | ||
working capital | 100.15M - | 16.67M 83.35% | 79.81M 378.68% | 34.67M 56.56% | 76.56M 120.86% |
All numbers in (except ratios and percentages)